Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Nitric oxide - Mallinckrodt

Drug Profile

Nitric oxide - Mallinckrodt

Alternative Names: Ik 7001; IK-3001; IK-7001; INOflo; INOmax; INOmax Total Care; INOMAX® Total Care package; INOtherapy; INOVENT

Latest Information Update: 06 Sep 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Massachusetts General Hospital
  • Developer AGA Linde Healthcare; Ikaria Holdings; Mallinckrodt plc
  • Class Anti-inflammatories; Antiacnes; Antiandrogens; Antibacterials; Antifibrotics; Antifungals; Antihypertensives; Antivirals; Diagnostic agents; Free radicals; Nitrogen oxides; Non-opioid analgesics; Small molecules; Vasodilators
  • Mechanism of Action Androgen receptor antagonists; Angiogenesis inducing agents; Cell death stimulants; Guanylate cyclase stimulants; Nitric oxide donors; Reactive oxygen species modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Hypoxic respiratory failure; Pulmonary hypertension
  • New Molecular Entity No

Highest Development Phases

  • Marketed Hypoxic respiratory failure; Pulmonary hypertension
  • Phase III Bronchopulmonary dysplasia; Pulmonary arterial hypertension
  • Preclinical Transplant rejection
  • Discontinued Heart failure; Reperfusion injury

Most Recent Events

  • 16 Apr 2019 Registered for Pulmonary hypertension (In adults) in Australia (Inhalation)
  • 12 Apr 2019 Launched for Pulmonary hypertension (In adults) in Australia (Inhalation)
  • 01 Apr 2019 Preclinical trials in Transplant rejection in USA (Parenteral) before April 2019 (Mallinckrodt pipeline, April 2019)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top